[The effect of mildronate on erythrocyte membrane permeability in experimental lung pathology].
With the use of the erythrocyte osmotic and acidic resistance methods, the experiments on intact albino rats by applying a model of chronic non-specific lung diseases and those in vitro have shown that mildronate has a membrane-stabilizing action only when given in high doses (500 mg/kg) and concentrations (10(-3)-10(-4) M). When used in low doses (5, 25, 50, and 200 mg/kg) and concentrations (10(-5)-10(-7) M), in produces no positive effect.
Antonenko
L I
LI
Frantsuzova
S B
SB
Arshinnikova
L L
LL
D000818:Animals; D002317:Cardiovascular Agents / Q000627:therapeutic use*; D002463:Cell Membrane Permeability / Q000187:drug effects*; D004305:Dose-Response Relationship, Drug; D004353:Drug Evaluation, Preclinical; D004910:Erythrocyte Membrane / Q000187:drug effects*; D066298:In Vitro Techniques; D008173:Lung Diseases, Obstructive / Q000097:blood / Q000188:drug therapy*; D008297:Male; D008763:Methylhydrazines / Q000494:pharmacology / Q000627:therapeutic use*; D009996:Osmotic Fragility / Q000187:drug effects; D051381:Rats; D013997:Time Factors
D002317:Cardiovascular Agents; D008763:Methylhydrazines; C050147:3-(2,2,2-trimethylhydrazine)propionate
Vliianie mildronata na pronitsaemost' éritrotsitarnykh membran pri éksperimental'noĭ patologii legkikh.